A qualitative interview study gauged patients’ experiences with belantamab mafodotin, which is used to treat relapsed/refractory multiple myeloma (RRMM) following failure on at least 4 prior therapies.
VIDEO: Novel agents in the multiple myeloma pipeline healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Andrew Kin, MD, expands on the ways BCMA-targeted therapies that are currently available and under development have shifted the treatment landscape for relapsed/refractory multiple myeloma, the implications of the approval of teclistamab, and the limitations that still exist for using BCMA-targeted agents.